Health officials have announced a significant medical advancement for approximately 500,000 menopausal women across the UK who are unable to use traditional hormone replacement therapy. The National Institute for Health and Care Excellence has approved a new daily non-hormonal tablet called Fezolinetant, also known by the brand name Veoza, for prescription on the NHS.
A Breakthrough Treatment for Restricted Patients
This innovative medication specifically targets women for whom HRT is unsuitable due to existing medical conditions, such as a history of blood clots, or personal choice. Manufactured by pharmaceutical company Astellas Pharma, Fezolinetant works by blocking specific nerve pathways in the brain responsible for triggering common menopausal symptoms like hot flushes and night sweats.
Addressing a Critical Treatment Gap
Helen Knight, director of medicines evaluation at NICE, emphasized the profound impact these symptoms have on quality of life and overall wellbeing. "For those who are unable to take HRT for varying reasons, options have historically been limited," she stated. "We have heard clearly from patients how difficult that can be."
The health spending watchdog confirmed that clinical evidence demonstrates Fezolinetant can meaningfully reduce symptoms while being cost-effective, offering value for taxpayers. However, women prescribed this treatment will require regular liver function monitoring as a safety precaution.
Transforming Lives and Expanding Choices
Dr Sue Mann, national clinical director in women's health for NHS England, welcomed the development as "very welcome news especially for women who are unable to or don't wish to take hormone replacement therapy." She explained that menopausal symptoms can affect every aspect of a woman's life, making this new option particularly valuable.
"It's another vital treatment option which could help hundreds of thousands of women experiencing menopause to better manage their symptoms and feel more in control of their health," Dr Mann added. The approval represents a substantial expansion of therapeutic choices available through the National Health Service for menopausal care.
By making this non-hormonal treatment available through the NHS, health authorities aim to provide much-needed relief to a substantial patient population that has previously faced limited alternatives. This development marks an important step forward in addressing the diverse needs of women navigating menopause with greater flexibility and personalized care options.
